Kenai Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 30

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $8M

  • Investors
  • 6

Kenai Therapeutics General Information

Description

Developer of an induced pluripotent stem cell-based cell therapy platform designed to develop disease-modifying treatments for Parkinson's disease and other central nervous system conditions, operating in the biotechnology and cell therapy sector. The company offers cryopreserved, allogeneic, off-the-shelf neuron replacement therapies and a gene-modified cell therapy platform for central nervous system disorders, enabling patients and healthcare systems to access scalable regenerative treatment approaches targeting neurodegenerative disease mechanisms.

Contact Information

Website
www.kenaitx.com
Formerly Known As
Ryne Biotechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • One Broadway
  • 14th Floor Kendall Square
  • Cambridge, MA 02142
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • One Broadway
  • 14th Floor Kendall Square
  • Cambridge, MA 02142
  • United States

Kenai Therapeutics Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kenai Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 05-Jan-2026 $8M Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 29-Feb-2024 Completed Pre-Clinical Trials
2. Grant 26-Jan-2023 $4M $5M Completed Pre-Clinical Trials
1. Seed Round 20-Jul-2022 $5M $5M Completed Pre-Clinical Trials
To view Kenai Therapeutics’s complete valuation and funding history, request access »

Kenai Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
Series A-1
Seed 5,000,000 $0.000010 $1 $1 1x $1 1.88%
To view Kenai Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Kenai Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an induced pluripotent stem cell-based cell therapy platform designed to develop disease-modifying treatmen
Drug Discovery
Cambridge, MA
30 As of 2026

Cambridge, MA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kenai Therapeutics Competitors (3)

One of Kenai Therapeutics’s 3 competitors is BlueRock Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BlueRock Therapeutics Formerly VC-backed Cambridge, MA
Aspen Neuroscience Formerly VC-backed San Diego, CA
Sumitomo Corporation Tokyo, Japan
You’re viewing 3 of 3 competitors. Get the full list »

Kenai Therapeutics Patents

Kenai Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026173911-A1 Engineered cell therapy with secreted antibodies targeting lrrk2 Pending 11-Feb-2025
WO-2026064194-A1 Methods and compositions for dosing a cell therapy for parkinson's disease Pending 18-Sep-2024
AU-2024334482-A1 Methods and compositions for engineered da neuronal cells Active 31-Aug-2023
AU-2024334482-C1 Methods and compositions for engineered da neuronal cells Active 31-Aug-2023
EP-4770680-A1 Methods and compositions for engineered da neuronal cells Pending 31-Aug-2023 C12N15/907
To view Kenai Therapeutics’s complete patent history, request access »

Kenai Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kenai Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alaska Permanent Fund Sovereign Wealth Fund Minority
Cure Ventures Venture Capital Minority
Euclidean Capital Family Office Minority
The Column Group Venture Capital Minority
California Institute for Regenerative Medicine Government
You’re viewing 5 of 6 investors. Get the full list »

Kenai Therapeutics FAQs

  • When was Kenai Therapeutics founded?

    Kenai Therapeutics was founded in 2022.

  • Where is Kenai Therapeutics headquartered?

    Kenai Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Kenai Therapeutics?

    Kenai Therapeutics has 30 total employees.

  • What industry is Kenai Therapeutics in?

    Kenai Therapeutics’s primary industry is Drug Discovery.

  • Is Kenai Therapeutics a private or public company?

    Kenai Therapeutics is a Private company.

  • What is Kenai Therapeutics’s current revenue?

    The current revenue for Kenai Therapeutics is .

  • How much funding has Kenai Therapeutics raised over time?

    Kenai Therapeutics has raised $86.8M.

  • Who are Kenai Therapeutics’s investors?

    Alaska Permanent Fund, Cure Ventures, Euclidean Capital, The Column Group, and California Institute for Regenerative Medicine are 5 of 6 investors who have invested in Kenai Therapeutics.

  • Who are Kenai Therapeutics’s competitors?

    BlueRock Therapeutics, Aspen Neuroscience, and Sumitomo are competitors of Kenai Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process